Leaner Teva Bolsters Margins With 2022 Expected To Be Trough Year
Generics Launches In 2022 Will ‘Affect The Second Half’ Of The Year
Executive Summary
Keeping a keen eye on costs through a multi-pronged strategy allowed Teva to bolster its margins and direct cash flow towards debt in 2021. But revenues declined and 2022 is set to be another bumpy year for the Israeli giant’s top line.
You may also be interested in...
Teva Moves Forward With LAI Olanzapine Trials
Teva is starting Phase III trials for a long-acting injectable formulation of olanzapine, partner MedinCell has revealed. The move comes after the pair were knocked back on their partnered risperidone product earlier this year by the US FDA, with a new expected launch date for that product now also disclosed by the French company.
Generics Industry Braces For New Wave Of Price Pressure
With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.
Teva Identifies Teriparatide Importance Amid US Launch Drought
Teva acknowledged that it was “not independent of the macro environment in the US,” as it saw another significant drop off for its North America generics business amid a lack of new launches. The Israeli giant took the unusual step of singling out a complex generic asset – its proposed generic to Eli Lilly’s Forteo – as “the most important” potential launch for its 2022 top line.